Systemic corticosteroid exposure during cutaneous immune related adverse events worsens overall survival

被引：0
|
作者：
Shah, N. [1 ,2 ]
Jacoby, T. V. [1 ,3 ]
Asdourian, M. S. [1 ,4 ]
LeBoeuf, N. [1 ]
Semenov, Y. R. [1 ]
Reynolds, K. [1 ]
Chen, S. [1 ,4 ]
机构：
[1] Mass Gen Brigham Inc, Dermatol, Boston, MA USA
[2] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA
[3] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2022年 / 142卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
LB933
引用
收藏
页码：B14 / B14
页数：1
相关论文
共 50 条
  • [1] Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer
    Thompson, Leah L.
    Yoon, Jaewon
    Krasnow, Nira A.
    Chang, Michael S.
    Li, Edward B.
    McMahon, Devon E.
    Chen, Steven T.
    JAMA DERMATOLOGY, 2021, 157 (05) : 599 - 602
  • [2] Oral and cutaneous immune-related adverse events in cancer patients: Prevalence and overall survival
    de Oliveira Filho, Osias Vieira
    Gibbons, Ivana Lameiras
    Medeiros, Yuri de Lima
    de Oliveira, Thiago Bueno
    Treister, Nathaniel Simon
    Alves, Fabio Abreu
    ORAL DISEASES, 2025, 31 (01) : 278 - 285
  • [3] Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors
    Hirotsu, Kelsey E.
    Scott, Madeleine K. D.
    Marquez, Cesar
    Tran, Anhthy T.
    Rieger, Kerri E.
    Novoa, Roberto A.
    Robinson, William H.
    Kwong, Bernice Y.
    Zaba, Lisa C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : 651 - 653
  • [4] Immune-related adverse events in patients treated with immunotherapy according to corticosteroid exposure
    Meraz-Brenez, Andres
    Aranda-Gutierrez, Alejandro
    Jael Soliz, Dhylan
    Reyes-Vanegas, Diego
    Gonzalez-Sanchez, Hector Raul
    Martinez-Cannon, Bertha Alejandra
    Verduzco-Aguirre, Haydee Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story
    Guven, Deniz Can
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05)
  • [6] Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
    Fan, Yong
    Xie, Wenhui
    Huang, Hong
    Wang, Yunxia
    Li, Guangtao
    Geng, Yan
    Hao, Yanjie
    Zhang, Zhuoli
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story
    Verheijden, Rik J.
    de Groot, Jolien S.
    Fabriek, Babs O.
    Hew, Miki N.
    May, Anne M.
    Suijkerbuijk, Karijn P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05) : 616 - 619
  • [8] Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
    Gu, Stephanie L.
    Nath, Sandy
    Markova, Alina
    PHARMACEUTICALS, 2023, 16 (11)
  • [9] Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy
    Asdourian, Maria S.
    Jacoby, Ted V.
    Shah, Nishi
    Otto, Tracey
    Thompson, Leah L.
    Dee, Edward Christopher
    Reynolds, Kerry L.
    Semenov, Yevgeniy R.
    Chen, Steven T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (06) : 1368 - 1370
  • [10] Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs)
    Maier, Tara
    Gu, Stephanie
    Shah, Neil J.
    Faleck, David M.
    Lacouture, Mario E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345